{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7","upperLimit":"9.6","value":"4.5"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"8.2","value":"1.5"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.0","upperLimit":"78.9","value":"71.4"},{"groupId":"OG001","lowerLimit":"22.2","upperLimit":"46.0","value":"33.3"}]}],"title":"Stable Disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.5","upperLimit":"29.0","value":"21.1"},{"groupId":"OG001","lowerLimit":"50.9","upperLimit":"75.1","value":"63.6"}]}],"title":"Progressive Disease (PD)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8","upperLimit":"7.5","value":"3.0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"8.2","value":"1.5"}]}],"title":"Not Assessable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"description":"Tumor Response of a subject was defined as the best tumor response (Complete Response \\[CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).\\], Partial Response \\[PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.\\], Stable Disease \\[SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.\\], or Progressive Disease \\[PD: at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study or unequivocal progression of existing non-target lesions, or appearance of new lesions.\\]) observed during the trial period and assessed according to RECIST v1.1 criteria. Results are based on central evaluation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks","id":"OG000","title":"Regorafenib (Stivarga, BAY73-4506)"},{"description":"Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS)","reportingStatus":"POSTED","timeFrame":"From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year","title":"Tumor Response","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}